Risks of Opioids in ST-Elevation Myocardial Infarction: A Review

Anne Henrieke Tavenier*, Renicus Suffridus Hermanides, Jan Paul Ottervanger, Peter Gerrit Johannes Ter Horst, Elvin Kedhi, Adriaan W. J. van't Hof

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

4 Citations (Web of Science)

Abstract

Although opioids are recommended and frequently used in the acute phase of ST-elevation myocardial infarction (STEMI), their use is accompanied by serious side effects. In particular, gastrointestinal adverse effects may disturb absorption of essential oral medication like platelet inhibitors. This may cause suboptimal platelet inhibition and increased risk of acute stent thrombosis. Some clinical studies have already demonstrated these negative results. Alternative strategies to optimize platelet inhibition and pain relief in STEMI are being investigated. Clinicians should become more aware of the potential side effects of opioids in STEMI.
Original languageEnglish
Pages (from-to)1303-1308
Number of pages6
JournalDrug Safety
Volume41
Issue number12
DOIs
Publication statusPublished - 1 Dec 2018

Keywords

  • PERCUTANEOUS CORONARY INTERVENTION
  • PLATELET INHIBITION
  • MORPHINE USE
  • SEGMENT ELEVATION
  • TABLETS
  • PAIN
  • ACETAMINOPHEN
  • REMIFENTANIL
  • AGGREGATION
  • ASSOCIATION

Cite this